Plymouth Meeting, PA – February 17, 2015: CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, today announced a new partnership with Vodafone. CRF Health will use Vodafone’s global Machine-to-Machine (M2M) platform to offer an enhanced service to clinical trial operators and their patients.
As a result of the partnership, managing mobile data sending in clinical studies using the TrialMax® eCOA platform is made significantly easier and more predictable for CRF Health clients. The agreement provides clinical trial sponsors running global studies with assured connectivity and instant access to data through Vodafone’s global network. Reliability, security and integration are crucial to ensure that healthcare industry requirements and standards are met.
“Having a trusted communications services partner is critical for us", comments CRF Health’s Vice President of Contracts and Vendor Management, Jaime Racine. She continues, "Partnering with Vodafone will help us provide our clients with more predictable data sending while improving the quality of our products and services”.
Vodafone Group’s Head of Machine-to-Machine Sales for Northern Europe, Cyril Deschanel, said, “Our global M2M platform and services allow CRF Health to confidently provide customers with reliable global end-to-end solutions for clinical trials to ensure the highest quality outcomes. Working together with CRF Health, we can achieve their goal of a seamless global experience and greater operational efficiency.”
For further information on CRF Health, please visit www.crfhealth.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.